Hyderabad has emerged as one of India's most important clusters for pharmaceutical research, generic drug manufacturing and technology services, home to everything from global capability centres to contract research organisations working on behalf of overseas parents. Each of these transactions includes an international related-party transaction and each of these transactions is now covered by a newly revised legal regime. Transfer pricing in India law is newly revised under the provisions of Income-tax Act, 2025 from 1 April 2026, superseding the previous 1961 Act and putting the whole of the system into a newly designated Chapter X (Section 161-173). It is the Income-tax Rules, 2026 published by the CBDT on 20 March 2026 which provide the operational details documentation, safe harbor and forms needed for companies involved in the pharmaceutical and technological industries in Hyderabad.
This article walks through the key areas Hyderabad-based pharma and tech companies need to get right under the current regime.
Transfer Pricing for Pharma Research and Technology Services
Hyderabad's pharma sector spans contract research organisations (CROs) conducting clinical and pre-clinical studies, contract manufacturers producing active pharmaceutical ingredients (APIs) and generic formulations and full-fledged R&D centres developing new drug candidates for global parents. Technology entities in the city range from software captives to specialised R&D units supporting group-wide platforms. Because these two sectors sit at very different points on the risk spectrum a routine CRO looks nothing like a full-risk drug developer correctly characterising each entity's function is the first and most important step before any benchmarking begins and the Act's tightened definitions of associated enterprise (Section 162) and international transaction (Section 163) make this characterisation exercise more consequential than it was under the old law.
Research, Development Support and Shared Service Transactions
Group‑wide research programmes often depend on shared functions such, as data management, regulatory affairs, quality assurance or lab and computing infrastructure. These shared functions are spread over entities and jurisdictions. It is essential to allocate the costs of these shared functions on a basis for example by using headcount project hours or usage metrics. One must also document that basis clearly. The reason is that the shared cost base is the foundation of the operating expense figure that is used for cost‑plus markups and when needed, for safe‑harbour margin calculations.
Intellectual Property, Royalty and Licence Arrangements
Pharma companies often. Get royalties for patented compounds, formulas and manufacturing knowledge while technology companies may get licenses for platforms, algorithms or brand names from their own group companies. These kinds of agreements need a DEMPE-style analysis. Looking at who does the Development, Enhancement, Maintenance, Protection and Exploitation work around the intangible asset not just who has the legal ownership of it. If a Hyderabad R&D unit plays a role, in creating drugs or key technology the way it is paid should show that role instead of treating it like a regular service.
Cost Allocation and Markup Determination
Once functions and shared costs are mapped, the appropriate markup needs to be determined and applied consistently. For CROs and technology captives operating on a cost-plus basis, this typically involves the Transactional Net Margin Method (TNMM) applied to operating margin. Contract R&D service providers in generic pharmaceuticals have a dedicated safe harbour category under Rule 89 of the Income-tax Rules, 2026, carrying a prescribed operating margin of 24% on operating cost, subject to a revenue cap of ₹300 crore. Software-related contract R&D and IT services, by contrast, have been consolidated into a unified "Information Technology Services" safe harbour category at 15.5% of operating expenses, with a threshold of ₹2,000 crore, applicable for a five-year block from Tax Year 2026-27. Businesses need to check carefully which category and which margin actually applies to their specific activity, since pharma contract R&D and software contract R&D now sit in structurally different safe harbour buckets with very different rates.
Benchmarking and Comparable Company Analysis
Where safe harbour isn't opted for or isn't available for the specific transaction, a full benchmarking exercise remains necessary identifying comparable independent companies, computing their margins and testing whether the tested party's results fall within an acceptable arm's length range. For pharma R&D and CRO work, comparable selection needs particular care around functional similarity, since companies that own or co-develop intellectual property make poor comparables for a routine service provider working purely on instructions from an overseas principal. It's also important to remember that choosing to enter into the harbour under Rule 93 comes with a cost. Once a taxpayer opts in they lose the right to use the Mutual Agreement Procedure under a tax treaty for that transaction. This means they can't seek resolution through treaty mechanisms if issues arise. So while the safe harbour provides an predictable outcome the loss of treaty relief must be considered carefully. The trade-off, between certainty and potential dispute resolution should be weighed thoughtfully.
Intercompany Agreements and Documentation Controls
Every transfer pricing position relies on the paperwork behind it being able to withstand scrutiny. Intercompany agreements should clearly outline the scope of research or technology services the basis for calculating royalties the triggers for payment and the manner in which risk is shared between the Hyderabad entity and its overseas affiliates. The Income‑tax Rules, 2026 require a three‑tiered documentation structure a Master File, a Local File and a Country‑by‑Country Report. The Local File requirement under Rule 84 applies even if a part of the business uses harbour. In practice I have seen that a qualified transfer pricing consultant will usually compare Intercompany agreements, with invoicing and cost data to make sure the two tell the same story.
Form 3CEB and Annual Compliance
The accountant's report long known as Form 3CEB has been renumbered as Form 48 under the new Rules, now covering eleven clauses across six parts with expanded disclosure requirements, including details specific to any safe harbour margins claimed. Form 48 must be filed for all international transactions regardless of whether safe harbour applies to part of them. A Form 3CEB filing consultant in Hyderabad working with pharma and technology clients needs to be fluent in this new form structure, the applicable safe harbour category for each transaction type and the revised filing timelines under the 2026 Rules.
Assessment, Audit and Dispute Risk Management
Pharma and technology entities that don't qualify for or don't opt into safe harbour remain fully exposed to regular transfer pricing scrutiny, where the Transfer Pricing Officer can recompute the arm's length price using the methods prescribed under Section 165. A newly introduced "block assessment" mechanism under the 2026 Rules allows multiple tax years to be examined in a single proceeding, which can reduce repeat scrutiny of the same transaction structure but also raises the stakes of getting the position right the first time. Budget 2026's move toward automatic, quasi-compensatory fees for procedural lapses replacing some of the older punitive penalty structure makes contemporaneous documentation and timely Form 48 filing more valuable, since reduced-penalty treatment depends on demonstrable good-faith compliance.
Professional transfer pricing support in Hyderabad
Pharma research and development royalty arrangements, technology service transactions and intercompany agreements need transfer pricing review under the Income-tax Act, 2025 and Income-tax Rules, 2026. SKMC Global support businesses with analysis, benchmarking safe harbour checks and Form 48 filing assistance. As a transfer pricing partner in Hyderabad SKMC Global support pharma and technology companies handle royalty comparisons, contract R&D margins and compliance documentation with practical planning.